form8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 2014
INTELLICELL BIOSCIENCES, INC.
| |
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
333-49388
|
|
91-1966948
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
460 Park Avenue, 17th Fl
New York, NY 10022
|
|
(Address of principal executive offices)
|
(646) 576-8700
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Amendment to Articles of Incorporation
On September 3, 2014, Intellicell Biosciences, Inc. (the “Company”) filed an amendment to the Company’s articles of incorporation with the Secretary of State of the State of Nevada to increase the Company’s authorized common stock from three billion five hundred million (3,500,000,000) shares of common stock to ten billion (10,000,000,000) shares of common stock. As disclosed in the Company’s definitive Schedule 14C as filed with the SEC on July 14, 2014, the amendment was approved by the Board of Directors on June 24, 2014 and by the vote of a majority of the voting capital stock of the Company on June 25, 2014.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
*Filed herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
INTELLICELL BIOSCIENCES, INC.
|
| |
|
|
|
|
|
| |
|
|
|
|
|
|
Date: September 9, 2014
|
|
By:
|
/s/ Dr. Steven Victor |
|
| |
|
|
|
Name: Dr. Steven Victor
|
|
| |
|
|
|
Title: Chief Executive Officer
|
|
3